Viking Therapeutics to Present Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting® 2024

Core Insights - Viking Therapeutics, Inc. announced that results from its Phase 2b clinical trial of VK2809 will be presented at the 75th Liver Meeting® 2024, focusing on nonalcoholic steatohepatitis (NASH) [1][2] Company Overview - Viking Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for metabolic and endocrine disorders, with three compounds currently in clinical trials [4] - The company leverages its expertise in metabolism to create innovative therapeutics aimed at improving patient outcomes [4] VK2809 Details - VK2809 is an orally available, selective thyroid hormone receptor beta agonist with a focus on liver tissue, showing potential in treating lipid disorders [3] - The Phase 2b VOYAGE study of VK2809 successfully met both primary and secondary endpoints in patients with biopsy-confirmed NASH and fibrosis [3] - In a Phase 2a study, VK2809 demonstrated significant reductions in LDL-C and liver fat content compared to placebo in patients with non-alcoholic fatty liver disease (NAFLD) [4] Upcoming Presentation - The oral presentation titled "Results from the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients with Biopsy-Confirmed NonAlcoholic Steatohepatitis and Fibrosis" will be delivered by Dr. Rohit Loomba on November 19, 2024, at the San Diego Convention Center [2]